Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

This Practice Guidance from the American Association for the Study of Liver Disease
(AASLD) intends to coalesce best practice recommendations for the identification of portal …

There is a universal agreement that the occurrence of clinical complications, such as ascites,
hepatic encephalopathy, gastrointestinal bleeding, and jaundice mark the transition from the …

Background & Aims Hepatocellular carcinoma (HCC) is a major cause of morbidity and
mortality in patients with advanced chronic liver disease (ACLD) caused by chronic hepatitis …

Background & Aims HCV-infected patients with cirrhosis achieve high sustained virological
response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic …

Traditionally, the complications of cirrhosis, namely variceal bleeding, ascites and hepatic
encephalopathy, were thought to result predominantly from circulatory dysfunction and …

Background & Aims As the long-term benefits of a sustained virological response (SVR) in
HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain undefined, we …

Background & Aims Non-invasive tests (NITs) for clinically significant portal hypertension
(CSPH; hepatic venous pressure gradient [HVPG]≥ 10 mmHg) have predominantly been …